The chronic wound: impaired healing and solutions in the context of wound bed preparation.

In the past few years, a different paradigm for the understanding and treatment of chronic wounds has emerged. The term used to describe this new context in which failure to heal is viewed is "wound bed preparation". This term is revolutionizing the way we approach chronic wounds, and has allowed chronic wounds to gain independence from established models of acute injury. Within the context of wound bed preparation, impaired healing and solutions to it are being addressed in novel ways. In this report, we make use of the diabetic ulcer as an example of a chronic wound, and emphasize the pathophysiological principles, the cellular and molecular abnormalities, and the solutions offered by the new approaches of gene therapy and stem cells. The emerging view is that chronic wounds are characterized by resident cells that have undergone phenotypic changes that need to be corrected for optimal healing to occur. We have established in animal models and in humans that stem cells have the potential to bring about fundamental changes in the repair process and, ultimately, a "quantum" jump in our therapeutic success.

[1]  V. Falanga,et al.  The longevity of a bilayered skin substitute after application to venous ulcers. , 2002, Archives of dermatology.

[2]  P. Quesenberry,et al.  The new stem cell biology. , 2002, Transactions of the American Clinical and Climatological Association.

[3]  M. Longaker,et al.  Studies in Fetal Wound Healing V. A Prolonged Presence of Hyaluronic Acid Characterizes Fetal Wound Fluid , 1991, Annals of surgery.

[4]  D. Margolis,et al.  A Literature Assessment of the Use of Miscellaneous Topical Agents, Growth Factors, and Skin Equivalents for the Treatment of Pressure Ulcers , 1995, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[5]  K. Brismar,et al.  Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. , 1999, Diabetes care.

[6]  R. Cooper,et al.  Micro-organisms and wounds. , 1996, Journal of wound care.

[7]  A. Hansson,et al.  Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of L‐lactate , 1998, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[8]  Keith Harding,et al.  Science, medicine and the future: healing chronic wounds. , 2002, BMJ.

[9]  F. Grinnell,et al.  Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. , 1992, The Journal of investigative dermatology.

[10]  William C. Parks,et al.  The Activity of Collagenase-1 Is Required for Keratinocyte Migration on a Type I Collagen Matrix , 1997, The Journal of cell biology.

[11]  C. Fife,et al.  The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1144 patients , 2002, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[12]  L. Phillips,et al.  Platelet-derived growth factor BB for the treatment of chronic pressure ulcers , 1992, The Lancet.

[13]  F. Gottrup Prevention of surgical-wound infections. , 2000, The New England journal of medicine.

[14]  T. Phillips,et al.  Biologic skin substitutes. , 1993, The Journal of dermatologic surgery and oncology.

[15]  I. K. Cohen,et al.  Physiology of the chronic wound. , 1998, Clinics in plastic surgery.

[16]  T. K. Hunt,et al.  Wound healing and wound infection. What surgeons and anesthesiologists can do. , 1997, The Surgical clinics of North America.

[17]  L. Bolton,et al.  Microbiology and Healing of the Occluded Skin‐Graft Donor Site , 1993, Plastic and reconstructive surgery.

[18]  M. Robson,et al.  Wound Infection: A Failure of Wound Healing Caused by an Imbalance of Bacteria , 1997 .

[19]  M. Auletta,et al.  Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers. , 1996, Biomaterials.

[20]  M. Longaker,et al.  Adult Skin Wounds in the Fetal Environment Heal with Scar Formation , 1994, Annals of surgery.

[21]  F. Grinnell,et al.  Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. , 1993, The Journal of investigative dermatology.

[22]  L D Solem,et al.  A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. , 1997, The Journal of burn care & rehabilitation.

[23]  Paul Martin,et al.  Wound Healing--Aiming for Perfect Skin Regeneration , 1997, Science.

[24]  F. Logerfo,et al.  Lack of association of diabetes with increased postoperative mortality and cardiac morbidity: results of 6565 major vascular operations. , 2002, Archives of surgery.

[25]  W. Eaglstein,et al.  The "trap" hypothesis of venous ulceration , 1993, The Lancet.

[26]  G. Winter,et al.  Formation of the Scab and the Rate of Epithelization of Superficial Wounds in the Skin of the Young Domestic Pig , 1962, Nature.

[27]  Jerry S. Vandeberg,et al.  Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. , 2000, Annals of surgery.

[28]  J. Mansbridge,et al.  Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. , 1998, Tissue engineering.

[29]  L. Broemeling,et al.  The Safety and Effect of Topically Applied Recombinant Basic Fibroblast Growth Factor on the Healing of Chronic Pressure Sores , 1992, Annals of surgery.

[30]  A. Falabella,et al.  Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. , 1997, Journal of dermatological science.

[31]  M. Robson,et al.  Bacterial quantification of open wounds. , 1969, Military medicine.

[32]  B H Perry,et al.  Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[33]  B. Gilchrest,et al.  Workshop on the pathogenesis of chronic wounds. , 1994, The Journal of investigative dermatology.

[34]  M. Robson,et al.  Wound healing alterations caused by infection. , 1990, Clinics in plastic surgery.

[35]  G. Schultz,et al.  Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[36]  T. K. Hunt,et al.  Effect of hyperoxia on vascular endothelial growth factor levels in a wound model. , 2000, Archives of surgery.

[37]  J. Lawrence,et al.  Wound infection under occlusive dressings. , 1991, The Journal of hospital infection.

[38]  I. Leigh,et al.  Clinical practice and biological effects of keratinocyte grafting. , 1991, Annals of the Academy of Medicine, Singapore.

[39]  D. Steed,et al.  Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. , 1996, Journal of the American College of Surgeons.

[40]  F. Logerfo,et al.  Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. , 1984, The New England journal of medicine.

[41]  V. Falanga Chronic wounds: pathophysiologic and experimental considerations. , 1993, The Journal of investigative dermatology.

[42]  J. Hansbrough,et al.  Clinical trials of a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. , 1997, The Journal of burn care & rehabilitation.

[43]  S. Werner,et al.  Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. , 1998, Experimental cell research.

[44]  T. Helfman,et al.  Occlusive dressings and wound healing. , 1994, Clinics in dermatology.

[45]  R. Allman,et al.  Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. , 1994, The American journal of pathology.

[46]  B. Gilchrest,et al.  Clinical applications of cultured epithelium. , 1992, Epithelial cell biology.

[47]  I. K. Cohen,et al.  Scarless wound healing in the mammalian fetus. , 1992, Surgery, gynecology & obstetrics.

[48]  G. O’Toole,et al.  The role of bacterial biofilms in ocular infections. , 2002, DNA and cell biology.

[49]  M. Longaker,et al.  Scarless healing. The fetal wound. , 1998, Clinics in plastic surgery.

[50]  J. Hansbrough,et al.  Clinical trials of a living dermal tissue replacement placed beneath meshed, split-thickness skin grafts on excised burn wounds. , 1992, The Journal of burn care & rehabilitation.

[51]  D. Faller,et al.  Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. , 1991, The Journal of clinical investigation.

[52]  S. Myers,et al.  Culturing skin in vitro for wound therapy. , 1995, Trends in biotechnology.

[53]  S. Kourembanas Hypoxia and carbon monoxide in the vasculature. , 2002, Antioxidants & redox signaling.

[54]  J. R. Mekkes,et al.  Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation , 1999, Archives of Dermatological Research.

[55]  B. Rubin,et al.  Safety, feasibility, and early efficacy of subfascial endoscopic perforator surgery: a preliminary report from the North American registry. , 1997, Journal of vascular surgery.

[56]  M. Sporn,et al.  Hypoxia upregulates the synthesis of tgf-β1 by human dermal fibroblasts , 1991 .

[57]  J. McMahon,et al.  Predicting healing of lower limb ulcers. , 1995, The Australian and New Zealand journal of surgery.

[58]  J. Isner,et al.  Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. , 1998, Journal of vascular surgery.

[59]  V. Falanga,et al.  Wounding of bioengineered skin: cellular and molecular aspects after injury. , 2002, The Journal of investigative dermatology.

[60]  M. Siroky Pathogenesis of bacteriuria and infection in the spinal cord injured patient. , 2002, The American journal of medicine.

[61]  V. Falanga,et al.  Low oxygen tension stimulates collagen synthesis and COL1A1 transcription through the action of TGF‐β1 , 2002, Journal of cellular physiology.

[62]  I. K. Cohen,et al.  Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. , 1996, The Journal of investigative dermatology.

[63]  A. Singer,et al.  Cutaneous wound healing. , 1999, The New England journal of medicine.

[64]  U. Tantry,et al.  Stimulation of fibroblast proliferation and matrix contraction by wound fluid. , 1997, International Journal of Biochemistry and Cell Biology.

[65]  L C Parish,et al.  Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor‐2) to accelerate wound healing in venous ulcers , 2001, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[66]  E. Middelkoop,et al.  Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. , 1998, The Journal of investigative dermatology.

[67]  F. Yao,et al.  Gene therapy in wound repair and regeneration , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[68]  A. Vaheri,et al.  Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. , 1996, The Journal of investigative dermatology.

[69]  H. Maibach,et al.  Effect of Air Exposure and Occlusion on Experimental Human Skin Wounds , 1963, Nature.

[70]  R. Tompkins,et al.  Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. , 1998, Human gene therapy.

[71]  K. Poskitt,et al.  Surgical correction of isolated superficial venous reflux reduces long-term recurrence rate in chronic venous leg ulcers. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[72]  W. Eaglstein,et al.  Inhibition of cell proliferation by chronic wound fluid , 1993, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[73]  L. Ovington Wound care products: how to choose. , 2001, Home healthcare nurse.

[74]  S. A. Bruce,et al.  Longitudinal study of in vivo wound repair and in vitro cellular senescence of dermal fibroblasts , 1991, Experimental Gerontology.

[75]  V. Falanga Classifications for wound bed preparation and stimulation of chronic wounds , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[76]  E. Dabelsteen,et al.  Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. , 1999, The Journal of investigative dermatology.

[77]  K. Burnand,et al.  Effect of venous ulcer exudates on angiogenesis in vitro , 2002, The British journal of surgery.

[78]  V. Falanga,et al.  Extravasation of macromolecules and possible trapping of transforming growth factor‐β in venous ulceration , 1995, The British journal of dermatology.

[79]  R. Kirsner,et al.  Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. , 1991, Journal of the American Academy of Dermatology.

[80]  M. Robson Growth factors as wound healing agents , 1992, Current Biology.

[81]  D. Faller,et al.  Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. , 1990, The Journal of clinical investigation.

[82]  J. Apelqvist Wound healing in diabetes. Outcome and costs. , 1998, Clinics in podiatric medicine and surgery.

[83]  D. Supp,et al.  Human dermal microvascular endothelial cells form vascular analogs in cultured skin substitutes after grafting to athymic mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  E Bell,et al.  Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. , 1981, Science.

[85]  A. Wysocki Evaluating and managing open skin wounds: colonization versus infection. , 2002, AACN clinical issues.

[86]  E. Middelkoop,et al.  Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. , 2002, European journal of cell biology.

[87]  G. G. Gallico Biologie Skin Substitutes , 1990 .

[88]  D. Steed Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. , 1995, Journal of vascular surgery.

[89]  T. Osler,et al.  Senescence and the healing rates of venous ulcers. , 2001, Journal of vascular surgery.

[90]  David G Armstrong,et al.  Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. , 2001, Diabetes care.

[91]  J. Ricotta,et al.  Use of Dermagraft, a Cultured Human Dermis, to Treat Diabetic Foot Ulcers , 1996, Diabetes Care.

[92]  W. Eaglstein,et al.  Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. , 1992, The Journal of dermatologic surgery and oncology.

[93]  S. Boyce,et al.  Design principles for composition and performance of cultured skin substitutes. , 2001, Burns : journal of the International Society for Burn Injuries.

[94]  M. Roberts,et al.  Defining a model to predict the distribution of topically applied growth factors and other solutes in excisional full-thickness wounds. , 1999, The Journal of investigative dermatology.

[95]  V. Falanga,et al.  Treatment of chronic wounds with bone marrow-derived cells. , 2003, Archives of dermatology.